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HD 12.58 years-95%CI:10.42-14.73-; TX 10.05-95%CI:7.45-12.65-; APD 6.09-95%CI:
3.43-8.74-; CAPD 10.69-95%CI: 6.14-15.23-.The LLPc-2009- in HD (6,547€-95%CI:
5,727€-7,366€-) was significantly higher (p0.001) than TX (5,079€-95%CI:4,127€-
6,030€-) or APD (4,359€-95%CI:3,064€-5,655€-) but not CAPD (5,785€-95%CI:4,302€-
7,269€-). PPYLtc was higher in HD than in TX, APD or CAPD in all the provided
scenarios. CONCLUSIONS: APD is the alternative with the lowest impact on indi-
rect costs due to morbidity. Besides, TX recipients also have higher rates of em-
ployment than HD and require less disability benefits.
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OBJECTIVES: Little information is available on the prevalence of post-transplant
events and resource utilization associated with such events in renal transplant (RT)
patients in clinical practice in Germany. The PORTRAIT study aims to describe the
health care resources used and to estimate the cost of managing post-transplant
patients using observational data from transplant databases and physician ques-
tionnaires from transplant centers across Europe. Aggregated study results have
been previously communicated; this abstract describes the results from two Ger-
man centers. METHODS: A retrospective observational study was undertaken in
which resource usage over three years was employed to derive costs from a third
party perspective, with results stratified by glomerular filtration rate (GFR) status at
one-year post transplant. Descriptive statistics were used to detail medical re-
source use and its costs. Post-transplant events considered were: hospitals stays,
delayed graft function, outpatient appointments, laboratory tests, anaemia, hyper-
tension, dyslipidaemia and infections. Immunosuppressant drug costs were not
considered in this analysis. RESULTS: Four hundred and fourteen patients from
both sites were included in the analysis. The total three-year cost of post-trans-
plant care by GFR at one year varies from a minimum of €20,632 per patient to a
maximum of €43,163 per patient. The average three-year costs decrease as a result
of improved graft functioning status (increased GFR) at one year. The average
three-year costs for a patient with a GFR45mL/ min/1.73 m2 at one year are 40%
lower than those patients with a GFR30 mL/ min/1.73 m2. CONCLUSIONS: In line
with the multinational results, the German results provide evidence that post-
transplant resource usage in a real-life treatment setting increases as post-trans-
plant renal function worsens. Therefore management strategies that promote re-
nal function post transplant are likely to provide important resource savings to the
health care system.
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OBJECTIVES: Overactive bladder syndrome (OAB) is a urological condition defined
by a set of symptoms including urgency, with or without urge incontinence, usually
with frequency and nocturia. Our aim was to assess the productivity and costs of
women with OAB in Hungary.METHODS: Cross-sectional survey was performed in
5 urology/gynecology outpatient centres. Demographic and clinical characteristics
were recorded. Medication, health and informal care utilisation were surveyed for
the past 12 months. The Work Productivity and Activity Impairment questionnaire
(WPAI) was used to assess productivity. Cost calculation was performed from the
societal perspective and human capital approach was used. RESULTS: Sixty-six
women with mean age of 56.9 (SD12.4) years participated in the study, 3 (5%)
singles, 38 (58%) married, 14 (21%) divorced and 11 (17%) widows. Forty-six (70%)
were in menopause and 45 (69%) were overweighted. Patients have had symptoms
for 6.6 (SD6.2) years in average, 62 (94%) had incontinence of whom 41 (66%)
experienced incontinence episodes daily and 30 (48%) used incontinence pads.
Twenty-six patients (39%) were taking medication for OAB and 22 (33%) had anti-
biotic treatment due to urinary symptoms in the past year. Patients had diverse
diagnostic procedures (e.g. ultrasound: 98%, cystometry 49%, uroflow 64%, cystos-
copy 20%), 10 (15%) were admitted to hospital due to urinary problem. Twenty-
three (35%) patients were working and 2 of them were on sick-leave in the past
year. WPAI results of active workers were: abstenteeism 0.04%, presenteeism
44.6%, impaired activity 48.2%, this latest was 50.7% for non-workers. Total costs
were €340/patient/year (conversion €1275.4 HUF), rate of direct medical, direct
non-medical and indirect cost was 92.6%, 6.8% and 0.6%, respectively.
CONCLUSIONS: Our study is the first to offer data on productivity and costs of
patients with OAB in Hungary. Results suggest that presenteesm is a major prob-
lem and direct medical costs (diagnostics, drugs) are dominant.
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OBJECTIVES: Complications are common following kidney transplantation. The
French Hospital National Database (PMSI) allows patients follow-up through their
hospitalization reports. This study assessed 4-year incidences of complications
after kidney transplantation and estimated their economic impact, in particular
renal complications.METHODS: From the years 2006-2010, hospitalization data for
all patients with kidney transplantation in year 2006 were extracted. Patients’ hos-
pital stays were followed during a period of 4 years. Major hospitalizations of in-
terests were pooled in renal, cardiovascular and infectious complications. Renal
complications were detailed in graft loss, acute renal insufficiency (ARI), acute
rejection (AR), recurrence of initial nephropathy (RIN), chirurgical complication
and, others. Incremental costs were estimated by subtracting transplantation-year
mean cost of patients without any renal complications to the one of those with
renal complications the same year. Mean annual costs of patients with graft loss
were assessed separately for each year. Costs were calculated according to the 2010
National Hospital Tariff and National Scale. RESULTS: A total of 2392 patients with
kidney transplantation in 2006 were identified. A total of 61.5% were males and
mean age was 45.0(14.9) years old. 4-year cumulative incidences of renal, cardio-
vascular and infectious complications were 54.8% (n1,311), 20.8% (n498) and
19.8% (n474). Incidences of ARI, AR, RNI, chirurgical complication and, others
renal complications were 24.5%, 21.1%, 4.1%, 3.1% and 22.4%, respectively. Com-
pared to other patients without any renal complication (First-year mean costs:
€25,170; Q1:€17,341–Q3:€27,649), the corresponding incremental costs for renal
complications were €7,046, €10,376, €10,238, €7,874 and, €5,668. During the 4-year
period, graft loss occurred in 4.4% patients. Annual mean costs of graft loss for the
first, second, third and fourth years were €32,159 (Q1:€11 723–Q3:€41,890) (n105),
€19,085 (n64), €25,269 (n52) and, €20,780 (n41), respectively. CONCLUSIONS:
After transplantation, short-term renal complications are frequent and expensive.
Intensive interventions on renal preservation and graft loss prevention are needed.
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OBJECTIVES: To evaluate the impact of treating urge urinary incontinence (UUI) on
health care resource utilization, productivity, activity impairment, and associated
costs. METHODS: The study used data (N75,000) from the 2011 National Health
and Wellness Survey, a self-administered, Internet-based questionnaire of a na-
tionwide sample of adults (age 18). Respondents with UUI or MUI were identified
via 3 Incontinence Questions. Respondents with stress urinary incontinence only,
prostate cancer, or (medication for) benign prostatic hyperplasia, were excluded.
UUI/MUI respondents were categorized as using prescription medication (Rx users)
for overactive bladder (OAB) and non-Rx users (who never used Rx and whose
condition reportedly interfered with life activities or was difficult to manage). Out-
come measures included health care utilization (type/number of resources used
within the past 6 months) and Work Productivity and Activity Impairment ques-
tionnaire-based scores. Direct and indirect costs were estimated using 2010 labor
and 2008 medical expenditure data sources. Generalized linear models predicted
resource use and productivity as a function of treatment status, adjusting for co-
variates (e.g., sociodemographics, BMI, OAB severity, UUI vs. MUI, and comorbid
status) that may also predict impairment. RESULTS:Among 1,190 UUI/MUI respon-
dents, 481 were defined as Rx and 709 as non-Rx users. Rx (vs. non-Rx) users were
more likely to be female (80.7% vs. 70.0%), older (mean62.7 vs. 53.1), non-Hispanic
White (82.3% vs. 69.7%), college educated, health-insured (94.6% vs. 81.7%), unem-
ployed/retired (72.6% vs. 57.7%), and reporting more moderate-to-severe OAB
(70.9% vs. 52.6%; all p0.05). Adjusting for covariates, Rx (vs. non-Rx) users had
lower activity impairment (41.1% vs. 46.8%), more provider visits (7.42 vs. 5.60) and
costs ($18,175 vs. $13,679), and higher total direct costs ($27,291 vs. $21,493), all
p0.01. CONCLUSIONS: UUI patients using, vs. never using, prescription medica-
tion reported lower activity impairment but higher direct costs. The findings may
inform the degree to which UUI pharmacotherapy affects health outcomes.
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OBJECTIVES: Comparing the costs of Solifenacin, Oxybutynin, Trospium chloride,
Tolterodine, Propiverine, and Darifenacine for the treatment of overactive bladder
(OAB) and incontinence in Germany. DATA AND METHODS: The cost-study is
based on a unique sickness fund dataset of 2.9 million insured persons which
included pharmaceutical, outpatient, inpatient, medical aids as well as remedies
data in 2009. 25,896 persons received anticholinergics and were classified as OAB
patients. 4,152 of these patients also suffered from incontinence. Multiple linear
regression models were performed to control for age and gender effects. Further-
more, a general approach (all costs were included) as well as a specific approach
(only costs associated with OAB were considered) were used. RESULTS: OAB pa-
tients caused additional costs of €2,492 using the general and €782 using the spe-
cific approach compared to Non-OAB patients. Patients treated with Propiverine
(€1,854) had the lowest additional costs under the general approach and patients
treated with Darifenacine (€3,230) the highest. In the specific approach, patients
treated with Propiverine (€691) had the lowest additional costs and patients treated
with Tolterodine (€1,124) the highest. In the special case of incontinence, patients
treated with Solifenacin have shown, by far, the lowest additional costs using
either approach (€3,216; €1,320). These results are mainly driven by the lower costs
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